NCT03742882已完成1 期
A Phase 1, Open-label, Multicenter, Single-dose Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Celgene
- 入组人数
- 40
- 试验地点
- 4
- 主要终点
- Pharmacokinetic- AUC0-t
研究概览
简要总结
This is a multicenter, open-label study to assess the PK of a single 200 mg oral dose of CC-90001 in subjects with mild, moderate, and severe hepatic impairment, and in matched healthy control subjects with normal hepatic function.
Degrees of hepatic impairment will be determined during screening by the subject's score according to Child-Pugh Classification Criteria.
详细描述
Subjects will be enrolled in Groups 1 through 5 as follows:
- Group 1: Approximately 6 to 8 male or female subjects with mild hepatic impairment (with a Child-Pugh score of ≥ 5 to ≤ 6) will be enrolled in Group 1.
- Group 2: Approximately 6 to 8 male or female subjects with moderate hepatic impairment (with a Child-Pugh score of ≥ 7 to ≤ 9) will be enrolled in Group 2.
- Group 3: Approximately 6 to 8 healthy male or female subjects with normal hepatic function will be enrolled in Group 3. Subjects in Group 3 will be matched to subjects in Group 2 with respect to sex, age (± 10 years), and weight (± 10% body mass index [BMI]). Group 3 will also serve as the control group for Group 1.
- Group 4: Approximately 6 to 8 male or female subjects with severe hepatic impairment (with a Child-Pugh score of ≥ 10 to ≤ 13) will be enrolled in Group 4.
- Group 5: Approximately 6 to 8 healthy male or female subjects with normal hepatic function will be enrolled in Group 5. Subjects in Group 5 will be matched to subjects in Group 4 with respect to sex, age (± 10 years), and weight (± 10% BMI).
This study employs a staged design as follows:
- Subjects with mild or moderate hepatic impairment and matching healthy subjects with normal hepatic function (Groups 1 through 3) will be enrolled concomitantly.
- At least 4 subjects with mild or moderate hepatic impairment must demonstrate satisfactory safety and tolerability for up to 4 days after dosing before subjects with severe hepatic impairment may be dosed.
- Two subjects with severe hepatic impairment must demonstrate satisfactory safety and tolerability for up to 4 days after dosing before the remaining subjects with severe hepatic impairment may be dosed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject must understand and voluntarily sign an Informed Consent Form (ICF) prior to any study-related assessments/procedures being conducted.
- •Subject is willing and able to adhere to the study visit schedule and other protocol requirements, including the restrictions.
- •Subject is male, or non-pregnant and non-nursing female between ≥ 18 and ≤ 70 years of age at the time of signing the ICF.
- •Subject has Body mass index (BMI) ≥ 18 and ≤ 40 kg/m2 at screening.
- •Female subjects NOT of childbearing potential must:
- •a. Have been surgically sterilized (hysterectomy or bilateral oophorectomy; proper documentation required) at least 6 months before Screening, or postmenopausal (defined as 24 consecutive months without menses before Screening, with a follicle-stimulating hormone [FSH] level in the postmenopausal range according to the laboratory used at Screening); FSH to be performed at the discretion of the Investigator in consultation with the Medical Monitor.
- •Females of childbearing potential (FCBP)1 must have a negative pregnancy test at the Screening and Baseline Visits. While receiving Investigational Product (IP) and for at least 28 days after taking the dose of IP, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below: Option 1: One highly effective method (e.g., hormonal contraception [oral, injection, implant, transdermal patch, vaginal ring]; intrauterine device; tubal ligation; or partner's vasectomy) and one additional form (latex condom or any nonlatex condom not made of natural [animal] membrane [eg, polyurethane], diaphragm, sponge).
- •OR Option 2: Male or female condom PLUS 1 additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
- •Male subjects must:
- •a. Practice true abstinence2 (which must be reviewed on a monthly basis and source documented) or agree to use a barrier method of birth control (condoms not made out of natural [animal] membrane [latex condoms were recommended]) during sexual contact with a pregnant female or female of FCBP while participating in the study, during dose interruptions, and for at least 28 days after the dose of investigational product, even if he has undergone a successful vasectomy.
- •Subject has clinical laboratory safety test results that are within normal limits or acceptable to the Investigator.
- •Subject is afebrile (febrile is defined as ≥ 38°C or 100.3°F), with supine systolic blood pressure ≥ 90 and ≤ 160 mm Hg, supine diastolic blood pressure ≥ 50 and ≤ 100 mm Hg, and pulse rate ≥ 40 and ≤ 100 beats per minute at Screening.
排除标准
- •The presence of any of the following will exclude a subject from enrollment:
- •Subject has any significant and relevant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study at the Investigator's discretion.
- •Subject has any condition that places the subject at an unacceptable risk if he or she were to participate in the study.
- •Subject has any condition that confounds the ability to interpret data from the study.
- •Subject is pregnant or breastfeeding.
- •Subject was exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever was longer).
- •Subject has used moderate or strong CYP3A4/5 inducers and/or inhibitors (including St. John's wort) within 30 days prior to dosing. The Indiana University P450 Drug Interactions Flockhart Table™ may be consulted for a list of such medications (http://medicine.iupui.edu/clinpharm/ddis/main-table).
- •Subject has any surgical or medical condition(s) possibly affecting drug absorption, distribution, metabolism, and excretion, eg, bariatric procedure. Subjects with appendectomy and cholecystectomy may be included.
- •Subject has an estimated creatinine clearance < 60 mL/min as calculated using the Cockcroft-Gault formula.
- •Subject has donated blood or plasma within 2 weeks before dose administration to a blood bank or blood donation center.
- •Subject has a history of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual) within 2 years before dose administration, or positive drug screening test reflecting consumption of illicit drugs unless positive drug screen is due to prescription drug use that is approved by the Investigator and the Medical Monitor.
- •Subject has a history of alcohol abuse (as defined by the current version of the Diagnostic and Statistical Manual) within 1 year before dose administration, or a positive alcohol screen.
- •Subject has had a positive result to the test for human immunodeficiency virus (HIV) antibodies at Screening.
- •Chronic or resolved Hepatitis B or Hepatitis C are acceptable only if sequelae are limited to hepatic involvement and its consequent comorbidities. (ie, vasculitis, clinically significant globulinemia, etc. are unacceptable).
- •Subject smokes more than 10 cigarettes per day, or the equivalent in other tobacco products (self-reported).
- •Subject has received live vaccination (excluding seasonal flu vaccination) within 30 days of dosing.
- •Subject is part of the clinical staff personnel or a family member of the study site staff.
- •Subject is, for any reason, deemed by the investigator to be inappropriate for this study, including a subject who is unable to communicate or to cooperate with the investigator or the clinical staff.
研究组 & 干预措施
Administration of CC-90001
Experimental
Single oral dose of 200 mg of CC-90001
干预措施: CC-90001 (Drug)
结局指标
主要结局
Pharmacokinetic- AUC0-t
时间窗: UP to approximately 7 Days
Estimation of AUC calculated from time zero to the last measured time point
Pharmacokinetic- t1/2
时间窗: Up to approximately 7 days
Estimation of terminal elimination half-life
Pharmacokinetic- AUC0-∞
时间窗: UP to approximately 7 Days
Estimation of AUC calculated from time zero to infinity
Pharmacokinetic- Cmax
时间窗: UP to approximately Day 1
Estimation of observed maximum plasma concentration
Pharmacokinetic- Tmax
时间窗: UP to approximately Day 1
Estimation of time to Cmax
Pharmacokinetic- CL/F
时间窗: Up to approximately 7 days
Estimation of apparent clearance of drug from plasma after extravascular administration
Pharmacokinetic- Vz/F
时间窗: Up to approximately 7 days
Estimation of apparent volume of distribution during the terminal phase
次要结局
- Adverse Events (AEs)(From enrollment until at least 28 days after completion of study treatment)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy SubjectsHepatic ImpairmentHealthy VolunteersNCT03824678Celgene40
已完成
1 期
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal ImpairmentRenal InsufficiencyNCT03097016Celgene48
已完成
1 期
A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic ImpairmentHealthy VolunteersHepatic ImpairmentNCT03983161Celgene39
已完成
1 期
A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult SubjectsHeathy VolunteerNCT03363815Celgene56
终止
1 期
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type PsoriasisParapsoriasisHealthy VolunteersNCT02502188Celgene24